Obermatt
See Similar Stocks →

Clarity Pharmaceuticals

ASX:CU6 · AU0000165375
PharmaceuticalsSmall

360

8
Profit price81
Owner Earnings Yield1
Dividend Yield1
Price/Sales1
EV / Gross Profit1
Price/Book10
Return on Capital9
Cash Return on Capital18
Return on Equity4
Profit margins13
Accruals22
Owner Earnings Margin4
Sales growth82
Profit growth7
Reinvestment93
Price momentum66
Debt load69
Refinancing28
Debt Payback1
Liquidity59
Analyst ratings100
Opinion Changes50
Price Target Upside93
Market mood100
Value Creation8/20creating some value
  • Creates more value than its capital costs
  • Owner earnings growing
  • Owner earnings per share growing
  • Reinvests at strong returns
  • Solid earnings base

What this means

Clarity Pharmaceuticals clears its cost of capital, but the record is mixed across the five tests. Real value creation, just not yet consistent.

Profile

CountryAustralia
IndustryPharmaceuticals
SizeSmall
TypePublic Company
ExchangeASX
Founded2010
Employees80
Websiteclaritypharmaceuticals.com
ISINAU0000165375
Last UpdateApr 2, 2026
Indices
ASX 300 (Australia)
Themes
UrologyOncologyBiotechnologyHealth CarePharmaceutical

Description

Analysis

Story stock

Clarity Pharmaceuticals Ltd is a story stock: the narrative is ambitious and the price reflects it, but the underlying numbers are weak.

Valuation data is not available for this company.

The trajectory is moderate and the balance sheet is adequate. The company scores 8/20 on our value-creation score: creating some value.

Nothing is flagged here: no red or amber gates, no divergence between profits and cash. That is itself information: the numbers are straightforward. As always: this describes the company's numbers; it is not a recommendation.

360° rank · history

1007550250
83
2026

All-time high

83

Jun 2026

All-time low

76

Mar 2026

Average rank

80

across all years

Detailed & Historical Ranks

Deep dive into 15 detailed ranks and 3 years of history.

Current202520242023
Price/Sales
1
—
—
—
Price/Earnings
76
—
—
—
Price/Book
10
—
—
—
Dividend Yield
1
—
—
—
Value (overall)
8
—
—
—

Cells are coloured by rank band (red weak → green strong). Sentiment & 360° history begins 2023.

Similar Stocks

The companies this stock is ranked against.

Compare Clarity Pharmaceuticals with its peers
Neuren Pharmaceuticals
ASX:NEU
29
CountryAustralia
IndustryPharmaceuticals
SizeSmall
Full Stock Analysis →
Aurelia Metals
ASX:AMI
69
CountryAustralia
IndustryMetals & Mining
SizeSmall
Full Stock Analysis →
Prenetics Global
NMQ:PRE
52
CountryHong Kong SAR China
IndustryHealth Care Providers & Services
SizeSmall
Full Stock Analysis →
Pharmicell
KSC:005690
35
CountrySouth Korea
IndustryBiotechnology
SizeSmall
Full Stock Analysis →
Charming Medical
NAQ:MCTA
22
CountryHong Kong SAR China
IndustryDiversified Consumer Services
SizeSmall
Full Stock Analysis →
NOVONIX
ASX:NVX
8
CountryAustralia
IndustryElectronic Equipment, Instruments & Components
SizeSmall
Full Stock Analysis →

Make Sense of the Ranks

Every rank runs 1–100 against true peers. Higher is always better.

360° View
1 · Watch OutGood· 100
Value
1 · ExpensiveGood Value· 100
Quality
1 · Weak FundamentalsHigh Quality· 100
Growth
1 · Tough TimesHigh Growth· 100
Safety
1 · High LeverageWell-Financed· 100
Sentiment
1 · SkepticismPositive· 100
Learn More →